Investors might want to bet on Amgen (AMGN), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most ...

Amgen (AMGN) closed at $366.44 in the latest trading session, marking a -2.06% move from the prior day. The stock's change was less than the S&P 500's daily gain of 0.72%. Elsewhere, the Dow gained 0.

Amgen has issued a voluntary recall for nearly 1 million bottles of the heart medication Corlanor (ivabradine) due to possible contamination. The nationwide recall was issued by the company on June 4 ...

By Puyaan Singh June 29 (Reuters) - The New England Journal of Medicine on Monday retracted an article on a pivotal clinical ...

By Jonathan Stempel July 1 (Reuters) - A federal judge on Wednesday blocked Colorado from capping the price of Amgen's ...

Weigh the financial strength of a pharma leader against the rapid growth, and risks, of a biotech newcomer as both navigate ...

If you are wondering whether Amgen stock still offers value at current levels, this article walks through what the numbers ...

Viridian Therapeutics has scored an FDA approval for Lumvoa to treat thyroid eye disease (TED), triggering competition with ...

Amgen recalls 934K bottles of Corlanor and Sensipar due to foreign material and manufacturing deviations, per FDA June 23 report.

Amgen announced 52-week results from a phase 2 trial with its weight-management candidate, MariTide. The results Amgen posted don't appear very competitive with Eli Lilly's weight management drug, ...

Amgen (AMGN) stock is in focus as an expert panel of the European Medicines Agency recommends withdrawal of the company's ...